Me

An Asset!
An Asset!
An Asset!
Saumitra
Rahatekar
saumitrarahatekar@gmail.com

+1 (848) 248 9998

02/23/09
 Current Scenario
• Obama administration supporting Stem cell - will translate into more
stem cell based therapeutics (Clinical Trials)

Obama Admin is having $300 billion dedicated to EHR for increasing

Healthcare efficiency

• Advent of Biogenerics will bring in more BA/BE studies

• More insurance companies are doing epidemiological studies on life

style, effect of diet et.al

Combinatorial Chemistry has increased the number of compounds to

be tested

• M & A are combining pipelines

Personalized medicine
 Current Scenarion
(contd.)
• Sentinel act of monitoring SAEs of drugs in market is new opportunity for
Makrocare

Adaptive trials for cutting costs and selecting doses

• Global operation for Clinical Research

• Abandoning $800 million R & D for a drug and moving to sub $300
million will lead to more outsourcing

• Imaging related Clinical Research services will grow @ 40 %

 Adv Makrocare

• End to end solutions (So less of information transfer issues)

Oracle CDMA, EDC, IVRS and back end IT capability focusing on inter-
operability

• This will help in doing Adaptive trials

• Presence in future mecca of Clinical Research - India , gives us Sun

advantage as well allowing to work 24X7

Presence in all major Therapy areas

• Global Presence - US, EU, Japan, India

Each day in getting the product in the market delay costs Pharma about
$7 million per day, Makrocare is well positioned to reduce this
 Business ideas
• Its costs nearly 40 cents to manage per $1 worth outsourced services

Bringing down these transaction costs for Pharma companies

• Reducing data management costs

• To see the world through partner’s eyes and forming joint term goals

New Business model involving partnerships with companies having

promising drugs but less finance to take it through, and getting
royalties from sales

• Introducing micro-dosing for faster human trials thus cutting costs for
partner

Focusing on protein therapeutics and nucleotides

* - elaborated in forthcoming slides
 Business ideas
(contd.)
Focusing on Animal Therapeutics market*

Focusing on universities*

Focusing on NGOs*

Keeping tab on John Hopkins, Cleveland Clinic, Mayo Clinic, Mass Gener
Hospital for their best practices and patient outsourcing

• Operations flexibility by using Sponsor’s recommended SOPs

• Creating online communities for getting feedback on services rendered

• Making customer feedback easier for customers

* - elaborated in forthcoming slides

 Business ideas
(contd.)
• Sharing details of # of projects a typical CRA handled simultaneously,
with the partner

Integration of Makrocare’s results/reports with clients existing

infrastructure for better (real time) decision making on behalf of client

• Considering Build-Operate-Transfer model for companies not having

presence in India

• Making reports smart phone enabled (read - iPhone)

• Adopting ‘Freemium’ by doling out free reports thus gaining top of mind
recall
 Animal Therapeutics
& Diagnostics
• Important Stats for Animal Therapeutics and Diagnostics

Total market - $22 billion

• Growth - 8 % p.a

• Total households in US with atleast one pet - 70 million

Top 4 companies - Pfizer, Wyeth, Merial, Intervet

• Trends - Vaccination, Animal Obesity and age related diseases

Universities Tech
transfer -
University Amount Comments
NYU $650 mln Remicade MAb- J & J
Columbia $135 mln
University of
$97.6 mln
California
Northwestern Pfizer’s Fibromylgia drug
$85 mln
University - Lyrica
Wake Forest Medical device to Kinetic
$71.2 mln
University Concepts
Massachusetts
General $346 mln
Hospital
Beckman
$118 mln
Research
Emory
$611 mln Giliead’s HIV - Emtriva
university
University of
$63.3 mln
Minnesota
University of
$53.3 mln Arthritis drug licensing
Rochester
 NGOs untapped
potential
• Cystic Fibrosis Foundation pours $76 million in Vertex Pharma
for Cystic Fibrosis drug

Leukemia & Lymphoma Society invested $3.7 million in Celator

Pharma for funding mid stage clinical trial for drug on Myeloid
Leukemia

• National Multiple Sclerosis Society paid $1 million for Apitope

International NV - Belgian Company

• Juvenile Diabetes Research foundation and Osiris Therapeutics

- $4 million for Stem cell based Diabetes treatment

• Michael J Fox commits $6 million for 3 Parkinson disease clinical

trials
 Recommendations
Nilesh Gupta - President Advanced Market - Lupin Pharma- “Saumitra is an
excellent sales person”. (Uses Thomson Pharma and Horizon Global) - This
recommendation was after I sold Lupin $ 140,000 product.

Sanjay Bettadpura, - Head Life Science Vertical - Edutech India - “Saumitra

brings in an infectious freshness and enthusiasm to the sales and marketing
process. Highly creative, and always looking for smarter ways to close deals,
he builds great rapport with his customers and genuinely looks to solving
their problems rather than just making a sale. Always up-to-date about the
industry , his domain knowledge in life sciences is a great plus. As a part of
my team, he was always the first to achieve his targets and needed little
guidance from me. He is self motivated, takes initiatives and has good
problem solving capabilities.His passion for the industry and single
mindedness to provide value to customers make a him a great sales and
business development person.”

Satheesh Muttathil - Sales training manager - Schering Plough - “Saumitra is

enterprising and professional in his approach and is very innovative while
executing his commitments. He is highly detail oriented and exhibits
 Why me
• MBA in Biotechnology with 6 years of experience in Life Sciences

Well versed with industry standards - CDISC, 21 CFR Part 11,IVRS, HL-7,
GCP, Ethics, eCTD et.al

• Doing certified course on SAS Clinical and Oracle Clinical Data

Management system

• Excellent presentation and communication skills

Good networking capabilities

• Uses Web2.0 tools like Linkedin, Twitter for sales leads

• Sold Centerwatch services to CROs

Tremendous appetite for knowledge

• Understands business - patronize Wall Street Journal and Harvard

Business Review
Why me (contd.)
Proactive

Never say die attitude

Out of box thinking

Passionate towards work

Diploma in Supply Chain

Management
 Saumitra Rahatekar
saumitrarahatekar@gmail.com
+1(848) 248 9998
+1(848) 248 9998
+1(848) 248 9998